48th Annual ICAAC / IDSA
46th Annual Meeting
October 25-28, 2008, Washington, DC

During the 48th ICAAC/46th IDSA conference new data were presented which provide additional guidance to clinicians regarding when to start ARV therapy, which boosted PIs should be used preferentially in initial therapy and whether some of the newer drugs now should be considered for use in treatment-naïve patients. Additionally, further studies established the safety and efficacy of simplifying ARV therapy with a one pill, once daily regimen or using a decreased dose of ritonavir when boosting some PIs. Last, several drugs in the HIV pipeline presented key data indicating their progress in development.

Physicians
USF Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Nurses (ANCC)
The University of South Florida College of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Pharmacists
USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Co-supported by an independent educational
grant from Gilead Sciences Medical Affairs
Co-supported by an educational grant from
Tibotec Therapeutics
*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings from the 48th Annual ICAAC/IDSA 46th Annual Meeting.